{"id":173084,"date":"2025-12-19T07:32:11","date_gmt":"2025-12-19T12:32:11","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=173084"},"modified":"2025-12-19T07:32:11","modified_gmt":"2025-12-19T12:32:11","slug":"why-india-still-depends-on-china-for-medicines","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/why-india-still-depends-on-china-for-medicines\/","title":{"rendered":"Why India Still Depends on China for Medicines"},"content":{"rendered":"
\n
\"\"<\/figure>\n<\/div>\n\n\n

India proudly wears the badge of being the \u201cpharmacy of the world.<\/a>\u201d And on the surface, that claim holds up. Indian companies ship affordable generic medicines to more than 200 countries. But beneath this success lies a vulnerability we don\u2019t talk about enough. While India manufactures the pills, it doesn\u2019t produce enough of the ingredients that actually make those pills work.<\/p>\n\n\n\n

Those ingredients are APIs, or Active Pharmaceutical Ingredients, the chemical compounds that give a drug its therapeutic punch. And APIs themselves depend on Key Starting Materials, or KSMs, which are the raw inputs used at the earliest stages of production. Think of it this way: if a finished medicine is a cake, APIs are the batter, and KSMs are the flour, sugar, and butter that go into it.<\/p>\n\n\n\n

The problem is that for many critical APIs and KSMs, India sources 60\u201370% of its supply from China. In some cases, the dependence is nearly total.<\/p>\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n
<\/div>\n\n\n\n

How India Gave Up the Chemical Backbone<\/h3>\n\n\n\n

This dependence didn\u2019t happen overnight. In the 1980s, India actually produced most of its APIs domestically. But over time, the economics began to shift. Environmental compliance became stricter, power and utility costs rose, and Chinese manufacturers started flooding the market with far cheaper alternatives.<\/p>\n\n\n\n

By the late 1990s and early 2000s, it simply made more business sense for Indian pharma companies to focus on formulations, the finished drugs rather than the messy, capital-heavy chemistry behind them. Gradually, the bulk of API and KSM manufacturing was outsourced to China. It was efficient, cost-effective, and for years, it worked just fine.<\/p>\n\n\n\n

Until it didn\u2019t.<\/p>\n\n\n\n

<\/div>\n\n\n\n

The Pandemic Wake Up Call<\/h3>\n\n\n\n

COVID-19 exposed the fragility of this setup. When Chinese factories shut down, the supply of common APIs dried up almost instantly. Prices of everyday drugs like paracetamol and azithromycin surged. Indian manufacturers were forced to slow production, and the so-called pharmacy of the world realised it didn\u2019t control its own supply chain.<\/p>\n\n\n\n

That shock triggered a long-overdue question: what happens if China stops supplying the raw materials?<\/p>\n\n\n\n

<\/div>\n\n\n\n

India\u2019s Attempt to Rebuild API Manufacturing<\/h3>\n\n\n\n

The government\u2019s answer came in the form of a \u20b97,000 crore Production Linked Incentive scheme aimed at reviving domestic API and KSM production. Alongside this, three bulk drug parks were approved in Gujarat, Andhra Pradesh, and Himachal Pradesh to lower infrastructure and compliance costs for manufacturers.<\/p>\n\n\n\n

Some companies responded quickly. Aurobindo Pharma<\/a> commissioned a \u20b92,400 crore facility to manufacture Penicillin G, a widely used antibiotic. Others, like Sun Pharma and Alkem Labs, began producing clavulanic acid, a key component of Augmentin.<\/p>\n\n\n\n

In just two years, close to \u20b93,000 crore has been invested under this push. On paper, it looks like momentum is building.<\/p>\n\n\n\n

But here\u2019s the catch, this still doesn\u2019t meaningfully dent India\u2019s dependence on China.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Why China Is So Hard to Replace<\/h3>\n\n\n\n

China\u2019s dominance in APIs isn\u2019t accidental. It\u2019s the result of decades of deliberate policy choices. As far back as the 1990s, China treated pharmaceuticals as a strategic industry. It offered cheap land, subsidised utilities, easy credit, and export-linked tax benefits. Over time, thousands of API manufacturers emerged across provinces like Jiangsu and Zhejiang.<\/p>\n\n\n\n

The real breakthrough came when China solved the environmental challenge. While Western countries pulled back from bulk drug manufacturing due to pollution concerns, China built dedicated chemical industrial parks with centralised waste treatment. This allowed manufacturers to scale production while keeping compliance costs low.<\/p>\n\n\n\n

Just as importantly, China built dense ecosystems. KSM suppliers, intermediate processors, and API plants operate close to one another, slashing logistics costs and reducing production delays.<\/p>\n\n\n\n

<\/div>\n\n\n\n

The Resource Advantage No One Talks About<\/h3>\n\n\n\n

There\u2019s another layer to China\u2019s edge: raw materials. Pharmaceutical chemistry relies heavily on specialty chemicals and rare earth elements used in catalysts, fermentation, and purification processes. China controls around 60\u201370% of global rare earth mining and dominates processing almost entirely.<\/p>\n\n\n\n

That means Chinese API producers don\u2019t just have cheaper access to these materials but they have assured access. For manufacturers outside China, sourcing these inputs consistently and competitively is a constant risk.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Labour and Infrastructure Seal the Deal<\/h3>\n\n\n\n

Labour costs further tilt the balance. According to World Bank data, if a Western API manufacturer has a wage index of 100, China sits around 8 and India around 10. That gap matters immensely in a cost-sensitive industry.<\/p>\n\n\n\n

Infrastructure is the final piece. Chinese API clusters integrate utilities, solvents, power, steam, and waste management within the same industrial zones. Indian manufacturers, despite recent progress, still face higher input costs and inconsistent utilities outside a handful of new parks.<\/p>\n\n\n\n

Put together, China\u2019s advantage rests on four pillars: policy support, access to critical minerals, low-cost labour, and deeply integrated infrastructure.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Where India Stands Today<\/h3>\n\n\n\n

India mastered formulations, branding, and global distribution. China mastered chemistry, scale, and cost control. And while India became indispensable to global healthcare, it quietly ceded the most capital and energy-intensive parts of the supply chain decades ago.<\/p>\n\n\n\n

Rebuilding that capability isn\u2019t quick. It requires massive scale, reliable utilities, environmental compliance, and long-term trust from global buyers especially in the US and Europe, where quality and traceability standards are tightening.<\/p>\n\n\n\n

<\/div>\n\n\n\n

A More Realistic Path Forward<\/h3>\n\n\n\n

India doesn\u2019t need to replace China entirely. It just needs to reduce its vulnerability. That means focusing on high-risk APIs like antibiotics and vitamins, ensuring bulk drug parks deliver genuinely low cost utilities, and encouraging large pharma companies to commit to long-term domestic sourcing contracts.<\/p>\n\n\n\n

If India prioritises fermentation based drugs, builds local intermediates to reduce feedstock dependence, and enforces strong quality and traceability standards, it can carve out a resilient base.<\/p>\n\n\n\n

Done right, this won\u2019t dethrone China. But it will ensure that the world\u2019s pharmacy isn\u2019t left scrambling when supply chains crack again. And maybe that\u2019s the real test of India\u2019s pharma future, not how much it exports, but how much of its own chemistry it can finally bring home.<\/p>\n","protected":false},"excerpt":{"rendered":"

India proudly wears the badge of being the \u201cpharmacy of the world.\u201d And on the surface, that claim holds up. Indian companies ship affordable generic medicines to more than 200 countries. But beneath this success lies a vulnerability we don\u2019t talk about enough. While India manufactures the pills, it doesn\u2019t produce enough of the ingredients […]<\/p>\n","protected":false},"author":1863,"featured_media":173086,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,5747],"tags":[1115],"class_list":["post-173084","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/Why-India-Still-Depends-on-China-for-Medicines.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":167470,"url":"https:\/\/alphastreet.com\/india\/sanofi-india-ltd-q3fy25-34-fall-in-profits\/","url_meta":{"origin":173084,"position":0},"title":"Sanofi India Ltd Q3FY25; 34% fall in Profits","author":"Chirag Gupta","date":"March 19, 2025","format":false,"excerpt":"Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines. Financial Results: Sanofi India Ltd reported Revenues for Q3FY25 of \u20b9515.00 Crores up from \u20b9469.00 Crore\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/4-9.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":179008,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-q3-fy26-earnings-results\/","url_meta":{"origin":173084,"position":1},"title":"Sun Pharmaceutical Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"February 2, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169131,"url":"https:\/\/alphastreet.com\/india\/suven-life-sciences-ltd-q4fy25-50-fall-in-revenue\/","url_meta":{"origin":173084,"position":2},"title":"Suven Life Sciences Ltd Q4FY25; 50% fall in Revenue","author":"Chirag Gupta","date":"July 14, 2025","format":false,"excerpt":"Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders. Financial Results: Suven Life Sciences Ltd reported Revenues for Q4FY25 of \u20b91.00 Crores down from \u20b92.00 Crore year on year, a fall of 50.0%. Total\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":147899,"url":"https:\/\/alphastreet.com\/india\/alphagraph-aurobindo-pharma-ltd-nse-auropharma-q4fy23-results-out-total-income-rises-13-yoy\/","url_meta":{"origin":173084,"position":3},"title":"Alphagraph | Aurobindo Pharma Ltd (NSE: AUROPHARMA): Q4FY23 Results Out; Total Income rises 13% YoY.","author":"Divyansh_Kasana","date":"May 31, 2023","format":false,"excerpt":"Aurobindo Pharma is a leading pharmaceutical company primarily involved in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company specializes in the production of APIs, which are the key components of pharmaceutical formulations. Aurobindo Pharma also focuses on the development, manufacturing, and distribution\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169622,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy26-earnings-results-20-fall-in-profits\/","url_meta":{"origin":173084,"position":4},"title":"Sun Pharmaceutical Industries Ltd Q1 FY26 Earnings Results – 20% fall in Profits","author":"Chirag Gupta","date":"July 31, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":157279,"url":"https:\/\/alphastreet.com\/india\/solara-active-pharma-sciences-ltd-q2fy24-26-rise-in-revenue\/","url_meta":{"origin":173084,"position":5},"title":"Solara Active Pharma Sciences Ltd Q2FY24; 26% rise in Revenue","author":"Chirag Gupta","date":"December 12, 2023","format":false,"excerpt":"Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. Financial Results: Solara Active Pharma Sciences Ltd reported Revenues for Q2FY24 of \u20b9425.00 Crores up from \u20b9338.00 Crore year on year, a rise of 25.74%. Total Expenses for\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-88.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/173084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=173084"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/173084\/revisions"}],"predecessor-version":[{"id":173087,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/173084\/revisions\/173087"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/173086"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=173084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=173084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=173084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}